Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Journal of Leukocyte Biology|June 24, 2010
Adaptor protein Lnk inhibits c-Fms-mediated macrophage functionSaskia Gueller, Helen S Goodridge, Birte Niebuhr, et al.
Oncotarget|December 20, 2014
Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotypeKatia Beider, Hanna Bitner, Merav Leiba, et al.
American Journal of Hematology|June 29, 2021
BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignanciesKatrin Herzog Tzarfati, Odit Gutwein, Arie Apel, et al.
Cancer|June 24, 2010
Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerantMaya Koren-Michowitz, Philipp le Coutre, Justus Duyster, et al.
Vox Sanguinis|May 16, 2023
Antiphospholipid antibodies in convalescent plasma of donors recovered from mild COVID-19 infectionDorit Blickstein, Marina Izak, Talia Filipovich-Rimon, et al.
Acta Haematologica|December 14, 2020
Management and Outcome of Venous Thrombosis in Patients with Myeloproliferative Neoplasms: Data from the Israeli MPN Working GroupOdit Gutwein, Noa Lavi, Merav Barzilai, et al.
Molecular Cancer Therapeutics|February 8, 2014
Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivoKatia Beider, Merav Darash-Yahana, Orly Blaier, et al.
Plos Medicine|February 20, 2009
Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patientNinette Amariglio, Abraham Hirshberg, Bernd W Scheithauer, et al.
Blood|September 4, 2012
Adaptor protein Lnk binds to and inhibits normal and leukemic FLT3De-Chen Lin, Tong Yin, Maya Koren-Michowitz, et al.
Annals of Hematology|September 13, 2019
Midostaurin in combination with intensive chemotherapy is safe and associated with improved remission rates and higher transplantation rates in first remission-a multi-center historical control studyTamar Berger, Uri Rozovski, Yakir Moshe, et al.
Pageof 7